Skip to main content
Premium Trial:

Request an Annual Quote

Abbott and Caprion Sign Research Deal for Lung Cancer Targets

NEW YORK, Feb. 4 (GenomeWeb News) - Caprion Pharmaceuticals and Abbott Laboratories will collaborate on lung cancer antibody drug targets, the companies said today.


Abbott will evaluate a number of Caprion's cell surface drug targets for non-small-cell lung cancer, and plans to add additional targets from an ongoing Caprion project. In its research, Caprion has been applying its CellCarta proteomics approach, comparing plasma membrane proteins from normal and cancer tissue samples.


Abbott will obtain exclusive worldwide rights to develop selected targets and commercialize drugs that target them.


Under the agreement, Caprion will receive an upfront payment, milestone payments, and royalties from future product sales.


Last year, Montreal-based Caprion Pharmaceuticals signed research collaborations with  AstraZeneca and  Wyeth.



The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.